Intrinsic value of NuVasive - NUVA

Previous Close

$52.18

  Intrinsic Value

$53.09

stock screener

  Rating & Target

hold

+2%

  Value-price divergence*

+307%

Previous close

$52.18

 
Intrinsic value

$53.09

 
Up/down potential

+2%

 
Rating

hold

 
Value-price divergence*

+307%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of NUVA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  18.62
  10.60
  10.04
  9.54
  9.08
  8.67
  8.31
  7.98
  7.68
  7.41
  7.17
  6.95
  6.76
  6.58
  6.42
  6.28
  6.15
  6.04
  5.93
  5.84
  5.76
  5.68
  5.61
  5.55
  5.50
  5.45
  5.40
  5.36
  5.33
  5.29
  5.26
Revenue, $m
  962
  1,064
  1,171
  1,282
  1,399
  1,520
  1,647
  1,778
  1,914
  2,056
  2,204
  2,357
  2,516
  2,682
  2,854
  3,033
  3,220
  3,414
  3,617
  3,828
  4,049
  4,279
  4,519
  4,770
  5,032
  5,306
  5,592
  5,892
  6,206
  6,535
  6,878
Variable operating expenses, $m
 
  876
  959
  1,046
  1,136
  1,231
  1,329
  1,431
  1,537
  1,647
  1,762
  1,832
  1,956
  2,085
  2,219
  2,358
  2,503
  2,655
  2,812
  2,976
  3,148
  3,326
  3,513
  3,708
  3,912
  4,125
  4,348
  4,581
  4,825
  5,080
  5,348
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  839
  876
  959
  1,046
  1,136
  1,231
  1,329
  1,431
  1,537
  1,647
  1,762
  1,832
  1,956
  2,085
  2,219
  2,358
  2,503
  2,655
  2,812
  2,976
  3,148
  3,326
  3,513
  3,708
  3,912
  4,125
  4,348
  4,581
  4,825
  5,080
  5,348
Operating income, $m
  124
  188
  212
  237
  263
  290
  318
  347
  377
  409
  442
  524
  560
  597
  635
  675
  716
  760
  805
  852
  901
  952
  1,005
  1,061
  1,120
  1,181
  1,244
  1,311
  1,381
  1,454
  1,531
EBITDA, $m
  227
  290
  319
  349
  381
  414
  449
  485
  522
  560
  601
  642
  686
  731
  778
  827
  877
  930
  986
  1,043
  1,103
  1,166
  1,231
  1,300
  1,371
  1,446
  1,524
  1,606
  1,691
  1,781
  1,875
Interest expense (income), $m
  13
  20
  23
  26
  29
  33
  36
  40
  44
  48
  52
  56
  61
  66
  71
  76
  81
  87
  92
  98
  105
  111
  118
  125
  132
  140
  148
  157
  166
  175
  185
Earnings before tax, $m
  65
  168
  189
  211
  233
  257
  282
  307
  334
  361
  390
  468
  499
  531
  564
  599
  635
  673
  713
  754
  796
  841
  888
  936
  987
  1,041
  1,096
  1,154
  1,215
  1,279
  1,346
Tax expense, $m
  30
  45
  51
  57
  63
  69
  76
  83
  90
  97
  105
  126
  135
  143
  152
  162
  172
  182
  192
  203
  215
  227
  240
  253
  267
  281
  296
  312
  328
  345
  363
Net income, $m
  37
  123
  138
  154
  170
  188
  206
  224
  243
  264
  284
  342
  364
  388
  412
  437
  464
  491
  520
  550
  581
  614
  648
  684
  721
  760
  800
  843
  887
  934
  983

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  154
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,571
  1,567
  1,724
  1,889
  2,060
  2,239
  2,425
  2,618
  2,819
  3,028
  3,245
  3,471
  3,706
  3,950
  4,203
  4,467
  4,742
  5,028
  5,327
  5,638
  5,963
  6,301
  6,655
  7,024
  7,410
  7,814
  8,236
  8,678
  9,140
  9,624
  10,130
Adjusted assets (=assets-cash), $m
  1,417
  1,567
  1,724
  1,889
  2,060
  2,239
  2,425
  2,618
  2,819
  3,028
  3,245
  3,471
  3,706
  3,950
  4,203
  4,467
  4,742
  5,028
  5,327
  5,638
  5,963
  6,301
  6,655
  7,024
  7,410
  7,814
  8,236
  8,678
  9,140
  9,624
  10,130
Revenue / Adjusted assets
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
Average production assets, $m
  279
  309
  340
  372
  406
  441
  477
  516
  555
  596
  639
  683
  730
  778
  828
  880
  934
  990
  1,049
  1,110
  1,174
  1,241
  1,310
  1,383
  1,459
  1,539
  1,622
  1,709
  1,800
  1,895
  1,995
Working capital, $m
  332
  265
  292
  319
  348
  379
  410
  443
  477
  512
  549
  587
  627
  668
  711
  755
  802
  850
  901
  953
  1,008
  1,065
  1,125
  1,188
  1,253
  1,321
  1,393
  1,467
  1,545
  1,627
  1,713
Total debt, $m
  626
  649
  740
  834
  933
  1,035
  1,142
  1,253
  1,368
  1,488
  1,613
  1,742
  1,877
  2,017
  2,163
  2,314
  2,472
  2,636
  2,808
  2,986
  3,172
  3,367
  3,570
  3,782
  4,004
  4,235
  4,478
  4,731
  4,996
  5,274
  5,565
Total liabilities, $m
  876
  899
  990
  1,084
  1,183
  1,285
  1,392
  1,503
  1,618
  1,738
  1,863
  1,992
  2,127
  2,267
  2,413
  2,564
  2,722
  2,886
  3,058
  3,236
  3,422
  3,617
  3,820
  4,032
  4,254
  4,485
  4,728
  4,981
  5,246
  5,524
  5,815
Total equity, $m
  695
  668
  735
  805
  878
  954
  1,033
  1,115
  1,201
  1,290
  1,383
  1,479
  1,579
  1,683
  1,791
  1,903
  2,020
  2,142
  2,269
  2,402
  2,540
  2,684
  2,835
  2,992
  3,157
  3,329
  3,509
  3,697
  3,894
  4,100
  4,316
Total liabilities and equity, $m
  1,571
  1,567
  1,725
  1,889
  2,061
  2,239
  2,425
  2,618
  2,819
  3,028
  3,246
  3,471
  3,706
  3,950
  4,204
  4,467
  4,742
  5,028
  5,327
  5,638
  5,962
  6,301
  6,655
  7,024
  7,411
  7,814
  8,237
  8,678
  9,140
  9,624
  10,131
Debt-to-equity ratio
  0.901
  0.970
  1.010
  1.040
  1.060
  1.090
  1.110
  1.120
  1.140
  1.150
  1.170
  1.180
  1.190
  1.200
  1.210
  1.220
  1.220
  1.230
  1.240
  1.240
  1.250
  1.250
  1.260
  1.260
  1.270
  1.270
  1.280
  1.280
  1.280
  1.290
  1.290
Adjusted equity ratio
  0.382
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  37
  123
  138
  154
  170
  188
  206
  224
  243
  264
  284
  342
  364
  388
  412
  437
  464
  491
  520
  550
  581
  614
  648
  684
  721
  760
  800
  843
  887
  934
  983
Depreciation, amort., depletion, $m
  103
  102
  107
  113
  119
  125
  131
  137
  144
  151
  159
  118
  126
  134
  143
  152
  161
  171
  181
  191
  202
  214
  226
  238
  252
  265
  280
  295
  310
  327
  344
Funds from operations, $m
  51
  225
  245
  267
  289
  312
  336
  362
  388
  415
  443
  459
  490
  522
  555
  589
  625
  662
  701
  742
  784
  828
  874
  922
  972
  1,025
  1,080
  1,137
  1,198
  1,261
  1,327
Change in working capital, $m
  -105
  25
  27
  28
  29
  30
  31
  33
  34
  35
  37
  38
  40
  41
  43
  45
  46
  48
  50
  53
  55
  57
  60
  62
  65
  68
  71
  75
  78
  82
  86
Cash from operations, $m
  156
  199
  219
  239
  260
  282
  305
  329
  354
  380
  407
  421
  450
  481
  512
  544
  578
  614
  651
  689
  729
  771
  814
  860
  907
  957
  1,008
  1,063
  1,119
  1,179
  1,241
Maintenance CAPEX, $m
  0
  -48
  -53
  -59
  -64
  -70
  -76
  -82
  -89
  -96
  -103
  -110
  -118
  -126
  -134
  -143
  -152
  -161
  -171
  -181
  -191
  -202
  -214
  -226
  -238
  -252
  -265
  -280
  -295
  -310
  -327
New CAPEX, $m
  -94
  -30
  -31
  -32
  -34
  -35
  -37
  -38
  -40
  -41
  -43
  -44
  -46
  -48
  -50
  -52
  -54
  -56
  -59
  -61
  -64
  -67
  -70
  -73
  -76
  -79
  -83
  -87
  -91
  -95
  -100
Cash from investing activities, $m
  -305
  -78
  -84
  -91
  -98
  -105
  -113
  -120
  -129
  -137
  -146
  -154
  -164
  -174
  -184
  -195
  -206
  -217
  -230
  -242
  -255
  -269
  -284
  -299
  -314
  -331
  -348
  -367
  -386
  -405
  -427
Free cash flow, $m
  -149
  122
  134
  148
  162
  177
  192
  209
  225
  243
  261
  267
  286
  307
  328
  350
  373
  396
  421
  447
  474
  501
  531
  561
  593
  626
  660
  696
  734
  773
  814
Issuance/(repayment) of debt, $m
  83
  85
  90
  94
  98
  103
  107
  111
  115
  120
  125
  130
  135
  140
  146
  152
  158
  164
  171
  179
  186
  194
  203
  212
  222
  232
  242
  253
  265
  278
  291
Issuance/(repurchase) of shares, $m
  30
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  111
  85
  90
  94
  98
  103
  107
  111
  115
  120
  125
  130
  135
  140
  146
  152
  158
  164
  171
  179
  186
  194
  203
  212
  222
  232
  242
  253
  265
  278
  291
Total cash flow (excl. dividends), $m
  -39
  207
  225
  242
  261
  279
  299
  320
  341
  363
  386
  396
  421
  447
  473
  501
  530
  561
  592
  625
  660
  696
  734
  773
  814
  857
  902
  950
  999
  1,051
  1,105
Retained Cash Flow (-), $m
  17
  -65
  -67
  -70
  -73
  -76
  -79
  -82
  -86
  -89
  -92
  -96
  -100
  -104
  -108
  -112
  -117
  -122
  -127
  -133
  -138
  -144
  -151
  -157
  -164
  -172
  -180
  -188
  -197
  -206
  -216
Prev. year cash balance distribution, $m
 
  92
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  235
  158
  172
  187
  203
  220
  237
  255
  274
  293
  300
  321
  343
  365
  389
  413
  439
  465
  493
  522
  552
  583
  616
  650
  685
  723
  761
  802
  845
  889
Discount rate, %
 
  4.90
  5.15
  5.40
  5.67
  5.96
  6.25
  6.57
  6.89
  7.24
  7.60
  7.98
  8.38
  8.80
  9.24
  9.70
  10.19
  10.70
  11.23
  11.79
  12.38
  13.00
  13.65
  14.33
  15.05
  15.80
  16.59
  17.42
  18.29
  19.21
  20.17
PV of cash for distribution, $m
 
  224
  143
  147
  150
  152
  153
  152
  150
  146
  141
  129
  122
  115
  106
  97
  88
  78
  68
  59
  51
  42
  35
  28
  22
  17
  13
  10
  7
  5
  4
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

FINANCIAL RATIOS  of  NuVasive (NUVA)

Valuation Ratios
P/E Ratio 71.1
Price to Sales 2.7
Price to Book 3.8
Price to Tangible Book
Price to Cash Flow 16.9
Price to Free Cash Flow 42.4
Growth Rates
Sales Growth Rate 18.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -13%
Cap. Spend. - 3 Yr. Gr. Rate 14.4%
Financial Strength
Quick Ratio 2
Current Ratio 0
LT Debt to Equity 81.2%
Total Debt to Equity 90.1%
Interest Coverage 6
Management Effectiveness
Return On Assets 3.1%
Ret/ On Assets - 3 Yr. Avg. 2.9%
Return On Total Capital 3.1%
Ret/ On T. Cap. - 3 Yr. Avg. 2.6%
Return On Equity 5.3%
Return On Equity - 3 Yr. Avg. 4.1%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 75.1%
Gross Margin - 3 Yr. Avg. 75.7%
EBITDA Margin 18.8%
EBITDA Margin - 3 Yr. Avg. 16.9%
Operating Margin 12.8%
Oper. Margin - 3 Yr. Avg. 10.8%
Pre-Tax Margin 6.8%
Pre-Tax Margin - 3 Yr. Avg. 6.4%
Net Profit Margin 3.8%
Net Profit Margin - 3 Yr. Avg. 3.3%
Effective Tax Rate 46.2%
Eff/ Tax Rate - 3 Yr. Avg. 8.2%
Payout Ratio 0%

NUVA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NUVA stock intrinsic value calculation we used $962 million for the last fiscal year's total revenue generated by NuVasive. The default revenue input number comes from 2016 income statement of NuVasive. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NUVA stock valuation model: a) initial revenue growth rate of 10.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.9%, whose default value for NUVA is calculated based on our internal credit rating of NuVasive, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of NuVasive.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NUVA stock the variable cost ratio is equal to 82.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for NUVA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for NuVasive.

Corporate tax rate of 27% is the nominal tax rate for NuVasive. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NUVA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NUVA are equal to 29%.

Life of production assets of 5.8 years is the average useful life of capital assets used in NuVasive operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NUVA is equal to 24.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $695 million for NuVasive - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 50.13 million for NuVasive is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of NuVasive at the current share price and the inputted number of shares is $2.6 billion.

RELATED COMPANIES Price Int.Val. Rating
ZBH Zimmer Biomet 119.51 45.88  str.sell
GMED Globus Medical 29.00 18.42  sell
OFIX Orthofix Inter 48.79 46.31  hold
KTWO K2M Group Hold 19.42 0.81  str.sell
RTIX RTI Surgical 4.85 1.09  str.sell
SYK Stryker 147.29 99.03  sell
SPNE SeaSpine Holdi 10.26 2.21  str.sell
EXAC Exactech 32.30 5.75  str.sell

COMPANY NEWS

▶ Alphatec Denounces Baseless NuVasive Complaint   [Oct-11-17 09:00AM  GlobeNewswire]
▶ NuVasive acquires startup with Duke University roots   [Sep-22-17 08:50AM  American City Business Journals]
▶ NuVasive Announces Acquisition Of Vertera Spine   [Sep-07-17 10:43AM  PR Newswire]
▶ InfoBionic Appoints Gene Cattarina to Board of Directors   [Aug-22-17 08:00AM  PR Newswire]
▶ ETFs with exposure to NuVasive, Inc. : August 14, 2017   [Aug-14-17 05:04PM  Capital Cube]
▶ Here's Why NuVasive Is Tanking Today   [Jul-28-17 12:49PM  Motley Fool]
▶ NuVasive beats 2Q profit forecasts   [12:28AM  Associated Press]
▶ Executive Changes Hit NuVasive Hard   [Jul-27-17 09:57PM  Motley Fool]
▶ ETFs with exposure to NuVasive, Inc. : May 30, 2017   [May-30-17 12:36PM  Capital Cube]
▶ ETFs with exposure to NuVasive, Inc. : May 8, 2017   [May-08-17 05:00PM  Capital Cube]
▶ ETFs with exposure to NuVasive, Inc. : April 28, 2017   [Apr-28-17 04:08PM  Capital Cube]
▶ NuVasive Straightens Up With Solid Growth   [Apr-25-17 06:28PM  Motley Fool]
▶ NuVasive beats 1Q profit forecasts   [04:46PM  Associated Press]
▶ Heres how much NuVasives 5 highest-paid executives earned   [07:20AM  American City Business Journals]
▶ NuVasive launching products to hit $100M market   [04:02PM  American City Business Journals]
▶ NuVasive Launches New Spinal Trauma Portfolio   [Apr-19-17 04:05PM  PR Newswire]
▶ NuVasive to Participate in Investor Events in March 2017   [Mar-02-17 05:34PM  PR Newswire]
▶ Masimo's Stock Is a Great Buy Right Now   [Feb-28-17 04:30PM  TheStreet.com]
Financial statements of NUVA
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.